Table 2.
Comparison between responders and nonresponders to sorafenib
| Responder (n = 11) | Nonresponder (n = 18) | P‐value | |
|---|---|---|---|
| Baseline characteristics | |||
| Age (year) | 68 (47–77) | 61 (38–89) | 0.081 |
| Gender (male/female) | 10‐Jan | 16‐Feb | >0.999 |
| Etiology—no. (%) | 0.788 | ||
| HBV | 6 (55%) | 11 (61%) | |
| HCV | 3 (27%) | 3 (17%) | |
| NBNC | 2 (18%) | 4 (22%) | |
| Vascular invasion‐no. (%) | 3 (27%) | 8 (44%) | 0.448 |
| Extrahepatic extension‐no. (%) | 4 (36%) | 12 (67%) | 0.142 |
| BCLC stage‐no. (%) | 0.667 | ||
| B | 4 (36%) | 5 (28%) | |
| C | 7 (64%) | 13 (72%) | |
| Child‐Pugh class‐no.(%) | 0.362 | ||
| A | 10 (91%) | 13 (72%) | |
| B | 1 (9%) | 5 (28%) | |
| Biochemical analysis | |||
| Albumin (g/dL) | 3.9 (2.8–4.5) | 3.7 (2.8–4.5) | 0.367 |
| Total bilirubin (mg/dL) | 0.9 (0.5–1.7) | 0.9 (1.0–2.1) | 0.648 |
| Prothrombin time (%) | 98.0 (65–122) | 76.5 (44–124) | 0.162 |
| Platelet (*104/μL) | 10.7 (5.9–31.6) | 9.8 (4.5–27.5) | 0.816 |
| Alpha‐fetoprotein (ng/mL) | 19.0 (3–1979) | 1195.5 (2–221 328) | 0.089 |
| AFP (L3%) | 25.1 (0.5–79.6) | 12.8 (0–64.9) | 0.097 |
| PIVKA‐II (mAU/mL) | 312 (20–5361) | 2176 (60–198 425) | 0.063 |
| FGF19‐pg/mL | 76.5 (26.9–434.1) | 153.0(27.6–980.5) | 0.807 |
| FGF21 (pg/mL) | 161.1(30.9–2491.4) | 215.4(15.9–2918.9) | 0.707 |
| ANG2 (pg/mL) | 2747 (1566–3724) | 3333 (1563–3728) | 0.296 |
| VEGF (pg/mL) | 253.7 (73.6–717.2) | 187.7 (84.0–732.2) | 0.912 |
| HGF (pg/mL) | 2869.5 (1760.8–4696.7) | 3612.8 (1630.1–6723.5) | 0.145 |
AFP, alpha‐fetoprotein; ANG2, angiopoietin 2; BCLC, Barcelona clinic liver cancer; FGF, fibroblast growth factor; HBV, hepatitis B virus; HCV, hepatitis C virus; HGF, hepatocyte growth factor; NBNC, non‐B non‐C; SD, stable disease, VEGF, vascular endothelial growth factor.